Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Joel Elconin

Moderna Rallies On Merck Collaboration: Can Drugmaker Replace COVID Vaccine Revenue?

In late 2020, when the world was searching for a vaccine or cure for COVID-19, the price action in Moderna Inc (NASDAQ:MRNA) was discussed frequently on Benzinga's PreMarket Prep show. 

Once the vaccines were developed and the issue ended its miraculous rally, the issue was discussed less and less.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.